Secondary end points: cumulative incidence of main posttransplant outcomes
| . | Single-unit UCB (n = 68) . | Double-unit UCB (n = 69) . | P . |
|---|---|---|---|
| 2-y CI of relapse | 23.5% ± 5.2% | 17.4% ± 4.6% | .31 |
| Day 100 acute GVHD | |||
| Grade ≥2 | 41.2% ± 6.0% | 44.9% ± 6.0% | .76 |
| Grade ≥3 | 25.0% ± 5.3% | 18.8% ± 4.7% | .40 |
| 2-y chronic GVHD | |||
| Overall | 50.0% ± 6.8% | 52.6% ± 6.7% | .70 |
| Extensive only | 14.7% ± 4.3% | 31.9% ± 5.7% | .02 |
| 2-y TRM | 5.9% ± 2.9% | 11.6% ± 3.9% | .25 |
| 2-y DFS | 67.6% ± 6.0% | 68.1% ± 6.0% | .74 |
| 2-y overall survival | 68.8% ± 6.0% | 74.8% ± 5.5% | .56 |
| . | Single-unit UCB (n = 68) . | Double-unit UCB (n = 69) . | P . |
|---|---|---|---|
| 2-y CI of relapse | 23.5% ± 5.2% | 17.4% ± 4.6% | .31 |
| Day 100 acute GVHD | |||
| Grade ≥2 | 41.2% ± 6.0% | 44.9% ± 6.0% | .76 |
| Grade ≥3 | 25.0% ± 5.3% | 18.8% ± 4.7% | .40 |
| 2-y chronic GVHD | |||
| Overall | 50.0% ± 6.8% | 52.6% ± 6.7% | .70 |
| Extensive only | 14.7% ± 4.3% | 31.9% ± 5.7% | .02 |
| 2-y TRM | 5.9% ± 2.9% | 11.6% ± 3.9% | .25 |
| 2-y DFS | 67.6% ± 6.0% | 68.1% ± 6.0% | .74 |
| 2-y overall survival | 68.8% ± 6.0% | 74.8% ± 5.5% | .56 |
CI, cumulative incidence.